Enveda Raises $311M Series E at $2B Valuation to Advance AI-Discovered Natural Medicines
Enveda, a biotech startup that uses AI to discover new drugs from the natural world, has raised a $311 million Series E at a $2 billion valuation. The round was led by Catalio Capital Management, with participation from Iconiq and other investors, and doubles the valuation the company reached 12 mo…
Read the full story at AI Insider ↗
Timeline · 1 report
- 2026-09-25 14:37 · AI Insider
Enveda Raises $311M Series E at $2B Valuation to Advance AI-Discovered Natural Medicines